On January 19, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity Smart platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the multi-year collaboration agreement, Guardant and Merck aim to:

Use Guardant’s portfolio of liquid and tissue biopsy tests as clinical trial enrolling assays in Merck’s global clinical studies,
Evaluate opportunities to develop novel therapies using Guardant liquid biopsy tests as a companion diagnostic, and
Partner for global commercialization of drugs and companion diagnostics including in US, Asia-Pacific, UK and EU markets.
"This strategic collaboration allows us to bring the power of the Infinity Smart platform to some of the most important oncology programs in development today," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "As biomarkers become more central to therapy selection, our goal is to ensure that every trial has the molecular clarity needed to reach the right patients. This collaboration strengthens our shared commitment to rigor, scale, and faster development of life-changing cancer therapies."

(Press release, Guardant Health, JAN 19, 2026, View Source [SID1234662086])